^
Association details:
| Biomarker: | PD-L1 expression + EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Response with pemrbolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R
Published date:
11/16/2021
Excerpt:
We describe a case of a patient with significant history of smoking and EGFR mutated programmed death ligand-1 (PD-L1) positive NSCLC who was initially treated with TKI therapy….While patient progressed on TKI therapy, he was able to achieve a durable response with a single PD-L1 agent, pembrolizumab.
DOI:
10.1177/10781552211057867
